Want to see HK:2126 full AI Analyst Report?
2126 Stock Chart & Stats
HK$2.50
-HK$0.02(-1.56%)
At close: 4:00 PM EST
HK$2.50
-HK$0.02(-1.56%)
Day’s Range― - ―
52-Week RangeHK$1.40 - HK$6.44
Previous CloseN/A
Volume104.00K
Average Volume (3M)2.67M
Market Cap
HK$700.11M
Enterprise ValueHK$750.27
Total Cash (Recent Filing)HK$503.28M
Total Debt (Recent Filing)HK$262.67M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding416,729,430
10 Day Avg. Volume1,852,649
30 Day Avg. Volume2,667,300
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.68
Price to Sales (P/S)3.39
P/FCF Ratio-11.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.77
Revenue Forecast (FY)HK$312.38M
Bulls Say, Bears Say
Bulls Say
Revenue Rebound & Better MarginsA +55% revenue rebound and ~43% gross margin in 2025 indicate durable underlying demand and improving unit economics for core CAR‑T products. Sustained top‑line momentum and healthier gross margins provide a structural runway to scale commercial operations and absorb fixed R&D/manufacturing costs if growth is maintained.
Marked Improvement In Cash BurnOperating cash flow narrowed materially, signaling effective cost control and working‑capital management. This structural reduction in cash burn lengthens the company’s financing runway, lowers immediate external funding needs, and reflects operational levers that management can sustain while continuing commercialization and scale-up efforts.
Manageable LeverageDebt-to-equity near 0.47 implies the company is not heavily reliant on debt financing, preserving financial flexibility. A moderate leverage profile reduces near‑term solvency risk and gives the firm scope to raise additional capital on less dilutive terms or invest in manufacturing capacity without an outsized interest burden.
Bears Say
Persistent Negative Cash GenerationConsistent negative operating and free cash flow is a structural weakness; despite improvement, the company still consumes cash annually. Continued outflows force reliance on external financing, heighten dilution risk, and constrain the firm’s ability to scale commercialization or sustain high R&D spend without securing fresh capital.
Equity Erosion Over TimeOngoing losses have materially reduced shareholders’ equity, weakening the balance sheet buffer. This erosion limits the company’s capacity to absorb setbacks, increases the probability of future dilutive capital raises, and reduces long‑term financial resilience versus peers with intact equity bases.
Deep Operating LossesVery large net losses and negative EBIT/EBITDA are structural profitability challenges; narrowing alone may be insufficient. Until the company achieves sustainable positive operating margins, its business model depends on continued funding rounds, which can delay reinvestment and commercialization plans and pose execution risk over the medium term.
JW (Cayman) Therapeutics Co. Ltd. News
2126 FAQ
What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?
JW (Cayman) Therapeutics Co. Ltd. lowest stock price was HK$1.40 and its highest was HK$6.44 in the past 12 months.
What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?
JW (Cayman) Therapeutics Co. Ltd.’s market cap is HK$700.11M.
When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?
JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 43 days.
How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?
JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Mar 26, 2026. The company reported -HK$0.777 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is JW (Cayman) Therapeutics Co. Ltd. overvalued?
According to Wall Street analysts JW (Cayman) Therapeutics Co. Ltd.’s price is currently Overvalued.
Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?
JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.
What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?
JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?
JW (Cayman) Therapeutics Co. Ltd. has 416,729,430 shares outstanding.
What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?
JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -HK$0.777 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.124%.
Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?
Currently, no hedge funds are holding shares in HK:2126
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JW (Cayman) Therapeutics Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
133.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.53%
Trailing 12-Months
Company Description
JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through treatments that harness the body's own immune cells to combat disease, notably including CAR-T therapies. Its leading therapeutic candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy designed to treat a variety of blood cancers. The company's innovative pipeline also features JWCAR129, an autologous CAR-T therapy for multiple myeloma; JWATM204, a TCR T-cell therapy candidate aimed at hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell receptor mimic therapy specifically targeting alpha-fetoprotein for HCC. Founded in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.
Technical Analysis
Alphamab Oncology
―
CARsgen Therapeutics Holdings Ltd.
―
Mabpharm Limited
―
CStone Pharmaceuticals
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―